{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2021"],"condition":["Solid tumor","Neoplasm Metastasis","Squamous Cell Carcinoma of Head and Neck","Carcinoma","NSCLC","Carcinoma, Non-Small-Cell Lung","Lung cancer","Advanced Solid Tumor","Colorectal Neoplasms","Refractory Tumor","Metastatic Tumor","Neoplasms"],"disease":["Squamous Cell Carcinoma Of Head And Neck","Neoplasm Metastasis","Solid Tumor","Carcinoma","Lung Cancer","Nsclc","Colorectal Neoplasms","Advanced Solid Tumor","Carcinoma, Non-small-cell Lung","Refractory Tumor","Metastatic Tumor","Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2393891"],"location":["United States"],"study_start_month":["11"],"keyword":["NK cells","Antibody","SNK01","SCCHN","IgG1","EGFR","ADCP","Natural killer cell","EGFR+","EGFR Positive","CD16A","Metastatic","ADCC","AFM24"],"repository":["ECRIN MDR"],"study_status":["Active, not recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers","description":"This is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.","dates":{"creation":"2021-11-15"},"accession":"2393891","cross_references":{"ClinicalTrials___gov":["NCT05099549"]}}